$Use of alendronate (4-amino-1-hydroxy-butylidene-1,1-bisphosphonate) to reduce fractures in osteoporotic females$

Use of alendronate (4-amino-1-hydroxy-butylidene-1,1-bisphosphonate) to reduce fractures in osteoporotic females

The use of alendronate or salt thereof in the manufacture of a medicament for reducing the risk of vertebral fractures in osteoporotic females. Alendronate is administered orally from 5mg to 20mg daily for a period of at least 2 years.

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	YATES, ASHLEY J, QUAN, HUI, CAPIZZI, THOMAS P, KARPF, DAVID B, SANTORA II, ARTHUR C
Format:	Patent
Sprache:	eng
Schlagworte:	ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The use of alendronate or salt thereof in the manufacture of a medicament for reducing the risk of vertebral fractures in osteoporotic females. Alendronate is administered orally from 5mg to 20mg daily for a period of at least 2 years.